This report argues that radioligand therapy (RLT) advancements are set to support the next phase in cancer care with its precision medicine approach. RLT uses radioactive molecules to kill cancer cells, sparing healthy tissue and limiting patient side effects.

Although the use of radiopharmaceuticals in cancer treatment is not new, recent advancements have enhanced their specificity, bringing a new era of precision medicine. Treating patients precisely with RLT is made possible by using targeted ligands that specifically bind to receptors or targets on cancerous cells, largely sparing normal cells from harm.

Treatment with RLT can be:

• personalised by selecting and interchanging radioisotopes or targeting compounds based on the patient’s disease characteristics
• customised for dosage and therapy duration based on the patient’s actual and predicted response
• monitored for treatment response through visualisation with scans.

To embrace the potential of RLT and take it from bench to bedside, this report presents three recommendations that leverage Australia’s robust reputation and expertise.